Viridian Therapeutics, Inc.\DE (VRDN) FCF Margin (2013 - 2026)
Viridian Therapeutics, Inc.\DE's (VRDN) quarterly FCF Margin came in at 84877.3% in Q1 2026, up 4392686.0% year-on-year from N/an in Q1 2025, and down 366.94% quarter-over-quarter from 18177.27% in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) FCF Margin (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's FCF Margin history runs 14 years deep, the most recent figure standing at 84877.3% for Q1 2026.
- On a quarterly basis, FCF Margin rose 4392686.0% year-over-year to 84877.3% in Q1 2026; TTM through Mar 2026 was 428.42%, a 9240139.0% increase from a year earlier, with the FY2025 full-year figure at 390.81%, up 7670522.0% from the prior year.
- FCF Margin slipped to 84877.3% in Q1 2026 per VRDN's latest filing, from 18177.27% in the prior quarter.
- Across five years, FCF Margin topped out at 120.08% in Q3 2025 and bottomed at 128804.17% in Q1 2025.
- The 5-year median for FCF Margin is 62809.72% (2024), against an average of 54443.15%.
- Biggest YoY gain for FCF Margin was 8383106 bps in 2025; the steepest drop was 6599444 bps in 2025.
- Year by year, FCF Margin stood at 32243.81% in 2022, then tumbled by 64 bps to 52844.44% in 2023, then plunged by 93 bps to 102008.33% in 2024, then jumped by 82 bps to 18177.27% in 2025, then sank by 367 bps to 84877.3% in 2026.
- Per Business Quant, the three latest VRDN FCF Margin figures stand at 84877.3% (Q1 2026), 18177.27% (Q4 2025), and 120.08% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.45% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Viridian Therapeutics, Inc.\DE | 631.55 Mn | 631.55 Mn | - | -84,877.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -84,877.30% |
| Dec 31, 2025 | -18,177.27% |
| Sep 30, 2025 | -120.08% |
| Jun 30, 2025 | -100,553.33% |
| Mar 31, 2025 | -128,804.17% |
| Dec 31, 2024 | -102,008.33% |
| Sep 30, 2024 | -79,068.60% |
| Jun 30, 2024 | -64,113.89% |
| Mar 31, 2024 | -62,809.72% |
| Dec 31, 2023 | -52,844.44% |
| Sep 30, 2023 | -54,704.17% |
| Jun 30, 2023 | -63,256.94% |
| Mar 31, 2023 | -63,355.10% |
| Dec 31, 2022 | -32,243.81% |
| Sep 30, 2022 | -1,776.90% |
| Jun 30, 2022 | -6,994.92% |
| Mar 31, 2022 | -9,824.54% |
| Dec 31, 2021 | -7,609.81% |
| Sep 30, 2021 | -5,798.56% |
| Jun 30, 2021 | -1,348.62% |